title: Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase.
abstract: The microsomal flavoprotein NADPH-cytochrome P450 oxidoreductase (CYPOR) is believed to function as the primary, if not sole, electron donor for the microsomal cytochrome P450 mixed-function oxidase system. Development of the mammalian embryo is dependent upon temporally and spatially regulated expression of signaling factors, many of which are synthesized and/or degraded via the cytochromes P450 and other pathways involving NADPH-cytochrome P450 oxidoreductase as the electron donor. Expression of CYPOR as early as the two-cell stage of embryonic development (The Institute for Genomic Research Mouse Gene Index, version 5.0, www.tigr.org/tdb/mgi) suggests that CYPOR is essential for normal cellular functions and/or early embryogenesis. Targeted deletion of the translation start site and membrane-binding domain of CYPOR abolished microsomal CYPOR expression and led to production of a truncated, 66-kDa protein localized to the cytoplasm. Although early embryogenesis was not affected, a variety of embryonic defects was observable by day 10.5 of gestation, leading to lethality by day 13.5. Furthermore, a deficiency of heterozygotes was observed in 2-week-old mice as well as late gestational age embryos, suggesting that loss of one CYPOR allele produced some embryonic lethality. CYPOR -/- embryos displayed a marked friability, consistent with defects in cell adhesion. Ninety percent of CYPOR -/- embryos isolated at days 10.5 or 11.5 of gestation could be classified as either Type I, characterized by grossly normal somite formation but having neural tube, cardiac, eye, and limb abnormalities, or Type II, characterized by a generalized retardation of development after approximately day 8.5 of gestation. No CYPOR -/- embryos were observed after day 13.5 of gestation. These studies demonstrate that loss of microsomal CYPOR does not block early embryonic development but is essential for progression past mid-gestation.
authors.affiliation: McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, Wisconsin 53706-1599, USA.
authors.forename: Anna L
authors.initials: AL
authors.lastname: Shen
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: O'Leary
authors.forename: Charles B
authors.initials: CB
authors.lastname: Kasper
mesh_terms: D000015:Abnormalities, Multiple / Q000201:enzymology* / Q000235:genetics; D000818:Animals; D003433:Crosses, Genetic; D005313:Fetal Death; D005865:Gestational Age; D006330:Heart Defects, Congenital / Q000196:embryology / Q000201:enzymology / Q000235:genetics; D051379:Mice; D018345:Mice, Knockout; D009251:NADPH-Ferrihemoprotein Reductase / Q000172:deficiency / Q000235:genetics*; D009436:Neural Tube Defects / Q000196:embryology / Q000201:enzymology / Q000235:genetics; D010641:Phenotype; D015183:Restriction Mapping; D017384:Sequence Deletion
chemical_list: D009251:NADPH-Ferrihemoprotein Reductase